应用等离子体手术系统对晚期卵巢癌行上腹部及膈肌初次肿瘤细胞减灭术
该研究在法国波尔多地区Bergonié癌症中心对51例FIGO IIIC-IV期卵巢癌患者系统使用PlasmaJet™行肿瘤细胞减灭术,其中41.2%(n=21)接受初次肿瘤细胞减灭术,58.8%(n=30)接受间歇性肿瘤细胞减灭术,78.4%(n=40)达到完全肿瘤细胞减灭。行膈肌剥离者中15.7%(n=8)需胸腔引流,作者认为该术式安全且有助于切除更多病灶而不增加并发症。
要点
- 51例FIGO IIIC-IV期卵巢癌患者系统使用PlasmaJet™行肿瘤细胞减灭术,78.4%达到完全肿瘤细胞减灭。
- 41.2%(n=21)接受初次肿瘤细胞减灭术,58.8%(n=30)接受间歇性肿瘤细胞减灭术。
- 行膈肌剥离者中15.7%(n=8)需胸腔引流,作者认为该术式安全且不增加并发症。
核心结论
- PlasmaJet™帮助术者完成上腹部区域的腹膜剥离,似乎使术者能切除更多病灶而不增加并发症,拓展了肿瘤细胞减灭与并发症之间的权衡空间。
研究设计与样本
- 病例历史与手术技术报告,2012年6月至2014年6月在法国波尔多地区Bergonié癌症中心对51例FIGO IIIC-IV期卵巢癌患者系统使用PlasmaJet™装置手术。
- 51例中41.2%(n=21)接受初次肿瘤细胞减灭术,58.8%(n=30)接受间歇性肿瘤细胞减灭术。
主要发现
- 51例中78.4%(n=40)达到完全肿瘤细胞减灭。
- 所报告病例为FIGO IVA期黏液性卵巢癌,行初次肿瘤细胞减灭术,达到无肉眼残留病灶的完全肿瘤细胞减灭,包括膈肌和腹部腹膜剥离。
- 该病例未发现术后并发症。
- 行PlasmaJet膈肌剥离的患者中15.7%(n=8)需胸腔引流。
临床怎么用
- 作者认为PlasmaJet™是一种安全、结构化的术式,可用于为卵巢癌患者取得最佳手术结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Electrically neutral argon plasma (PlasmaJet™) technology is a surgical option that helps to get an aggressive cytoreduction in selected patients with ovarian cancer because it can be directly applied by the surgeon to treat the tissue surface [1,2]. Upper abdominal surgical procedures are an important part of the surgery in these patients [3], there is a 22% complications rate when they are performed [4]. We present a surgical approach to ovarian cancer debulking using PlasmaJet™. METHODS: Case history and operative technique: 51 women supported for ovarian cancer Stage IIIC-IV were operated with systematic use of the PlasmaJet device at the Regional Institute Bergonié Cancer Center of Bordeaux, France between June 2012 and June 2014. 41.2% (n=21) patients underwent a Primary Debulking Surgery (PDS) and 58.8% (n=30) underwent an Interval Debulking Surgery. 78.4% (n=40) of the 51 patients studied had a complete cytoreduction. We present the case of a woman diagnosed with a mucinous ovarian carcinoma FIGO stage IVA, who underwent a PDS. Complete cytoreduction to no macroscopic disease was achieved, this included diaphragmatic and abdominal peritoneal stripping. RESULTS: No post-operative complications were found in this case. 15.7% (n=8) of patients undergoing diaphragmatic stripping with the PlasmaJet required a pleural drain. It is a safe structured procedure, which could be performed to achieve optimal surgical results for patients with ovarian cancer. CONCLUSIONS: PlasmaJet™ helps the surgeon to perform a peritoneal stripping of the upper abdominal areas and appears to enable the surgeon to remove more disease without increased morbidity, pushing the cytoreduction/morbidity tradeoff.
引用
- Cordeiro Vidal G, Babin G, Querleu D, et al. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer. Gynecol Oncol. 2016. PMID: 27836207. doi:10.1016/j.ygyno.2016.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。